当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication.

5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication.

Abstract：

AIM:To determine whether a 5-day regimen with rabeprazole, clarithromycin and amoxicillin (RCA) was as effective as a 7-day regimen. METHODS:A total of 139 H. pylori-infected patients were randomized to receive either a 5-day or 7-day course of rabeprazole 10 mg b.d., clarithromycin 400 mg b.d. and amoxicillin 750 mg b.d. Eradication was assessed by CLO test, histology and 13C-urea breath test. RESULTS:On the intention-to-treat basis, eradication rates were 66% (46 out of 70) and 84% (58 out of 69) for the 5- and 7-day regimens, respectively (P < 0.05). Using per protocol analysis, eradication rates were 70% (46 out of 66) and 91% (58 out of 64) for the 5- and 7-day regimens, respectively (P < 0.01). Adverse events, which were observed in 14 patients from each group, caused discontinuation of treatment in only two patients, resulting in excellent compliance. CONCLUSIONS:Our 5-day regimen of RCA yielded inferior results, whereas the 7-day regimen achieved an eradication rate exceeding 90% on the per protocol basis. Therefore, treatment regimens of less than 7 days for proton pump inhibitor-clarithromycin-amoxicillin therapies cannot be recommended.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Isomoto H,Furusu H,Morikawa T,Mizuta Y,Nishiyama T,Omagari K,Murase K,Inoue K,Murata I,Kohno S

doi

10.1046/j.1365-2036.2000.00892.x

subject

Has Abstract

pub_date

2000-12-01 00:00:00

pages

1619-23

issue

12

eissn

0269-2813

issn

1365-2036

pii

apt892

journal_volume

14

pub_type

临床试验,杂志文章,随机对照试验

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon.

    abstract：BACKGROUND:Conventional interferon monotherapy fails to achieve virological clearance in most hepatitis C-infected patients. The use of high-dose induction regimens may improve the initial clearance of virus, while the addition of ribavirin appears to improve the rates of sustained response once clearance is achieved. ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2002.01201.x

    authors： Malik AH,Kumar KS,Malet PF,Ostapowicz G,Adams G,Wood M,Yarbrough K,Jones A,Lee WM

    更新日期：2002-03-01 00:00:00

  • Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients.

    abstract：BACKGROUND:Chronic hepatitis C (HCV) treatment with pegylated-interferon (PEG-IFN)/ribavirin (RBV) is often limited by preexisting medical, psychiatric and psychosocial contraindications. However, limited data exist in general patient populations. AIM:To evaluate the percentage of HCV-infected patients in the general ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12200

    authors： Talal AH,LaFleur J,Hoop R,Pandya P,Martin P,Jacobson I,Han J,Korner EJ

    更新日期：2013-02-01 00:00:00

  • The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C.

    abstract：BACKGROUND:Intrahepatic non-hypervascular hypointense nodules (NHHNs) detected during the hepatobiliary phase of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) have the potential to transition into typical hypervascular hepatocellular carcinoma (HCC). However, ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15490

    authors： Toyoda H,Tada T,Yasuda S,Mizuno K,Sone Y,Kaneoka Y,Maeda A,Akita T,Tanaka J,Kumada T

    更新日期：2019-12-01 00:00:00

  • Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma--a long-term follow-up study.

    abstract：BACKGROUND:The long-term outcome of percutaneous acetic acid injection (PAI) and percutaneous ethanol injection (PEI) for treating small hepatocellular carcinoma (HCC) remains unclear. AIM:To compare the long-term outcome of PAI vs. PEI for treating small HCC. METHODS:From July 1998 to July 2004, 125 patients with sm...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03702.x

    authors： Tsai WL,Cheng JS,Lai KH,Lin CP,Lo GH,Hsu PI,Yu HC,Lin CK,Chan HH,Chen WC,Chen TA,Li WL,Liang HL

    更新日期：2008-08-01 00:00:00

  • Review article: can post-operative recurrence in Crohn's disease be prevented?

    abstract：:The decision regarding prophylactic treatment after surgery in Crohn's disease (CD) requires a good estimation of the risk of recurrence. It is also important to consider the consequences of recurrence for the patient, and the risks and benefits of treatment, bearing in mind that it will be given over a long period. S...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2006.03055.x

    authors： Lémann M

    更新日期：2006-10-01 00:00:00

  • Haemodynamic responses to 1.25 and 2 mg of terlipressin intravenously in man.

    abstract：:The systemic and hepatic haemodynamic effects following terlipressin (Glypressin) administration were studied. Bolus intravenous injections of 1.25 and 2 mg significantly decreased wedged hepatic vein pressure gradient by 29% and 31%, respectively. With each dose there was a small increase in mean arterial blood press...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1988.tb00709.x

    authors： Freeman JG,Barton JR,Record CO

    更新日期：1988-08-01 00:00:00

  • Review article: primary prophylaxis for portal hypertensive bleeding in cirrhosis.

    abstract：:Variceal bleeding is a consequence of portal hypertension, which in turn is the major complication of hepatic cirrhosis. Given the high rate of mortality of the first bleeding episode, primary prophylaxis to prevent bleeding from varices and portal hypertensive gastropathy is the current optimal therapeutic approach. ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2000.00778.x

    authors： Vlachogiannakos J,Goulis J,Patch D,Burroughs AK

    更新日期：2000-07-01 00:00:00

  • Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects.

    abstract：BACKGROUND:Omeprazole has become available in a tablet formulation, a Multiple Unit Pellet System (MUPS) containing a large number of small individually enteric-coated micropellets. AIM:To compare the acid-inhibitory effect of omeprazole MUPS 20 mg with pantoprazole 40 mg and to describe the pharmacokinetics of both d...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章

    doi：10.1046/j.1365-2036.2000.00806.x

    authors： Geus WP,Mathôt RA,Mulder PG,Lamers CB

    更新日期：2000-08-01 00:00:00

  • Serology-based criteria for adult coeliac disease have excellent accuracy across the range of pre-test probabilities.

    abstract：BACKGROUND:The revised paediatric criteria for coeliac disease allow omission of duodenal biopsies in symptomatic children who have specific serology and coeliac disease-associated genetics. It remains unclear whether this approach is also applicable for adults with various clinical presentations. AIM:To evaluate the ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15109

    authors： Fuchs V,Kurppa K,Huhtala H,Laurila K,Mäki M,Collin P,Salmi T,Luostarinen L,Saavalainen P,Kaukinen K

    更新日期：2019-02-01 00:00:00

  • Analysis of the cag pathogenicity island and IS605 of Helicobacter pylori strains isolated from patients with gastric cancer in Japan.

    abstract：BACKGROUND:CagA protein is encoded by the cagA gene, which is part of the cag pathogenicity island (PAI) in Helicobacter pylori. Insertion sequence (IS) elements are a diverse set of specialized DNA segments that can move to new sites in bacterial genomes. AIM:To determine the role of cagPAI and IS605 in the developme...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2004.01982.x

    authors： Deguchi R,Igarashi M,Watanabe K,Takagi A

    更新日期：2004-07-01 00:00:00

  • Localization of the beta(beta)3-adrenoceptor in the human gastrointestinal tract: an immunohistochemical study.

    abstract：BACKGROUND:Activation of human and non-human colonic beta(beta)3-adrenoceptors causes smooth muscle relaxation. beta3-Adrenoceptor agonists protect against experimental indomethacin-induced jejunal ulceration. The mechanism of protection may involve spasmolytic/vasodilatory agonist activity. The precise localization of...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.1998.00345.x

    authors： Anthony A,Schepelmann S,Guillaume JL,Strosberg AD,Dhillon AP,Pounder RE,Wakefield AJ

    更新日期：1998-06-01 00:00:00

  • Increased risk of developing Crohn's disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease.

    abstract：BACKGROUND:Anti-TNFα agents have revolutionised management of chronic inflammatory diseases. Paradoxically, these agents might provoke development of de novo autoimmune diseases. AIM:To examine whether there is an increased risk of developing Crohn's disease (CD) and ulcerative colitis (UC) while under treatment with ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15370

    authors： Korzenik J,Larsen MD,Nielsen J,Kjeldsen J,Nørgård BM

    更新日期：2019-08-01 00:00:00

  • Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment.

    abstract：BACKGROUND:Helicobacter pylori infection is a major cause of the progress of gastric glandular atrophy, a high-risk background factor in the development of gastric cancer. Regression of gastric atrophy is critical to prevention of cancer by H. pylori eradication treatment. However, it is controversial whether gastric a...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.16.s2.17.x

    authors： Sugiyama T,Sakaki N,Kozawa H,Sato R,Fujioka T,Satoh K,Sugano K,Sekine H,Takagi A,Ajioka Y,Takizawa T,H. Pylori Forum Gastritis Study Group.

    更新日期：2002-04-01 00:00:00

  • Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.

    abstract：BACKGROUND:Orlistat reduces energy uptake by the impairment of fat digestion and some evidence indicates it also lowers plasma cholesterol. AIM:To examine total, low-density lipoprotein- and high-density lipoprotein cholesterol during a weight reducing regimen, and assess the effect of orlistat in lowering cholesterol...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2004.01966.x

    authors： Erdmann J,Lippl F,Klose G,Schusdziarra V

    更新日期：2004-06-01 00:00:00

  • Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer?

    abstract：BACKGROUND:Triple therapy currently forms the cornerstone of the treatment of patients with Helicobacter pylori-positive duodenal ulcer. AIM:To establish whether prolonged antisecretory therapy is necessary in patients with active duodenal ulcer. METHODS:A total of 77 patients with H. pylori-positive duodenal ulcer w...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2001.01020.x

    authors： Tepes B,Krizman I,Gorensek M,Gubina M,Orel I

    更新日期：2001-07-01 00:00:00

  • Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth.

    abstract：BACKGROUND:Small intestinal bacterial overgrowth and sugar malabsorption (lactose, fructose, sorbitol) may play a role in irritable bowel syndrome. The lactulose breath test is a reliable and non-invasive test for the diagnosis of small intestinal bacterial overgrowth. The lactose, fructose and sorbitol hydrogen breath...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2005.02493.x

    authors： Nucera G,Gabrielli M,Lupascu A,Lauritano EC,Santoliquido A,Cremonini F,Cammarota G,Tondi P,Pola P,Gasbarrini G,Gasbarrini A

    更新日期：2005-06-01 00:00:00

  • Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease.

    abstract：BACKGROUND:The effect of anti-viral treatment on downstream costs for hepatitis C virus (HCV)-infected patients is unknown. AIM:To evaluate follow-up costs in patients with chronic HCV, stratified by liver disease severity. METHODS:Using a US private insurance database, mean all-cause per-patient-per-month (PPPM) US ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12454

    authors： Gordon SC,Hamzeh FM,Pockros PJ,Hoop RS,Buikema AR,Korner EJ,Terrault NA

    更新日期：2013-10-01 00:00:00

  • Review article: inflammatory bowel disease--empowering the patient and improving outcome.

    abstract：:Inflammatory bowel disease, in common with most chronic diseases, is managed by specialist clinicians during regular clinic follow-up visits. Patients spend approximately 1 h per year with clinicians, with few provisions made for patient participation in their own management for the remainder of the year, resulting in...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2004.02061.x

    authors： Robinson A

    更新日期：2004-10-01 00:00:00

  • Autoimmune cholestatic liver disease in people with coeliac disease: a population-based study of their association.

    abstract：BACKGROUND:Population data supporting an association between the autoimmune cholestatic liver diseases, primary biliary cirrhosis and primary sclerosing cholangitis and coeliac disease, is limited and at times contradictory. AIM:To explore the relationship between coeliac disease and both primary biliary cirrhosis and...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2005.02328.x

    authors： Lawson A,West J,Aithal GP,Logan RF

    更新日期：2005-02-15 00:00:00

  • Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs.

    abstract：BACKGROUND:Non-steroidal anti-inflammatory drugs have been implicated in reports of liver injury. However, the precise risk of non-steroidal anti-inflammatory drugs for this rare complication is unknown. AIM:To review systematically the published literature of population-based epidemiological studies reporting the inc...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2004.02092.x

    authors： Rubenstein JH,Laine L

    更新日期：2004-08-15 00:00:00

  • Meta-analysis: combination therapy with interferon-alpha 2a/2b and ribavirin for patients with chronic hepatitis C previously non-responsive to interferon.

    abstract：BACKGROUND:The efficacy of interferon-alpha plus ribavirin treatment for patients not responding to interferon monotherapy is not well established. AIM:To assess the efficacy and safety of combination therapy with interferon-alpha 2a/2b plus ribavirin by performing a meta-analysis of randomized clinical trials. METHO...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,meta分析,评审

    doi：10.1046/j.1365-2036.2002.01328.x

    authors： San Miguel R,Guillén F,Cabasés JM,Buti M

    更新日期：2002-09-01 00:00:00

  • Clinical trial: normal diet vs. partial replacement with oral E028 formula for the prevention of gastrointestinal toxicity in cancer patients undergoing pelvic radiotherapy.

    abstract：BACKGROUND:Acute gastrointestinal symptoms affect 90% of patients during pelvic radiotherapy. Elemental diet is protective in animal models. A nonrandomized study suggested benefit from a partial elemental diet. A pilot study suggested that radiotherapy patients only tolerate oral elemental diet comprising one-third of...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2008.03665.x

    authors： McGough C,Wedlake L,Baldwin C,Hackett C,Norman AR,Blake P,Harrington K,Tait D,Khoo V,Frost G,Andreyev HJ

    更新日期：2008-06-01 00:00:00

  • Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.

    abstract：BACKGROUND:The guaiac faecal occult blood test (G-FOBT), HemoccultSENSA, is sensitive for significant neoplasms [colorectal cancer (CRC), advanced adenomatous polyps (AAP)], but faulted by non-specificity for human haemoglobin (Hb). Quantified, Hb- specific, immunochemical faecal occult blood tests (I-FOBT) are now use...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2008.03898.x

    authors： Rozen P,Levi Z,Hazazi R,Waked A,Vilkin A,Maoz E,Birkenfeld S,Niv Y

    更新日期：2009-02-15 00:00:00

  • Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease.

    abstract：BACKGROUND:Transplacental transfer of tumour necrosis factor-alpha (TNF-α) inhibitors has been shown in mothers receiving therapy for inflammatory bowel disease (IBD). AIM:To examine reports of adverse events of these medications in pregnancy. METHODS:Individual Safety Reports of adverse events (Jan 2003-June 2012) w...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.12936

    authors： Deepak P,Stobaugh DJ

    更新日期：2014-11-01 00:00:00

  • Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection.

    abstract：BACKGROUND:Clearance of hepatitis B surface antigen (HBsAg) indicates clinical control of hepatitis B virus (HBV) infection. However, little is known about the impact of viral genomic variations on HBsAg loss. METHODS:We explored the association between viral genomic factors and HBsAg loss in 2121HBeAg-negative patien...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13170

    authors： Tseng TC,Liu CJ,Chen CL,Yang WT,Yang HC,Su TH,Wang CC,Kuo SF,Liu CH,Chen PJ,Chen DS,Kao JH

    更新日期：2015-05-01 00:00:00

  • The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy.

    abstract：AIM:To investigate the efficacy of two omeprazole triple therapies for the eradication of Helicobacter pylori, ulcer healing and ulcer relapse during a 6-month treatment-free period in patients with active duodenal ulcer. METHODS:This was a double-blind, randomized study in 15 centres across Canada. Patients (n = 149)...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.1999.00471.x

    authors： Zanten SJ,Bradette M,Farley A,Leddin D,Lind T,Unge P,Bayerdörffer E,Spiller RC,O'Morain C,Sipponen P,Wrangstadh M,Zeijlon L,Sinclair P

    更新日期：1999-03-01 00:00:00

  • Treatment and prevention of relapse of mild oesophagitis with omeprazole and cisapride: comparison of two strategies.

    abstract：BACKGROUND:Oesophagitis is usually a chronic condition. Healing with omeprazole is often followed by early relapse. Combination treatment and subsequent maintenance treatment with the prokinetic cisapride may be of benefit in relapse prevention. METHODS:Patients with endoscopically proven oesophagitis, grade I (n = 12...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1995.tb00382.x

    authors： Kimmig JM

    更新日期：1995-06-01 00:00:00

  • Injection of botulinum toxin before pneumatic dilatation in achalasia treatment: a randomized-controlled trial.

    abstract：BACKGROUND:Pneumatic dilatation is the first line therapy in achalasia, but half of patients relapse within 5 years of therapy and require further dilatations. AIM:To assess whether botulinum toxin injection before pneumatic dilatation is superior to pneumatic dilatation alone in achalasia patients. METHODS:Newly dia...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.2006.03083.x

    authors： Mikaeli J,Bishehsari F,Montazeri G,Mahdavinia M,Yaghoobi M,Darvish-Moghadam S,Farrokhi F,Shirani S,Estakhri A,Malekzadeh R

    更新日期：2006-09-15 00:00:00

  • Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients.

    abstract：:Thirteen patients with Zollinger-Ellison syndrome were investigated: 8 without, and 5 with, previous gastric surgery. After 7-34 months of treatment with famotidine, 8 out of 13 patients were resistant to this drug. Omeprazole 60 mg/day was administered to these 8 patients; after one month, the dose was reduced to 40 ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.1993.tb00086.x

    authors： Corleto V,Annibale B,D'Ambra G,Saggioro A,Ferrua B,Cassetta MR,Delle Fave G

    更新日期：1993-04-01 00:00:00

  • Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study.

    abstract：BACKGROUND:Pancreatic exocrine insufficiency (PEI) results in maldigestion, leading to abdominal pain, steatorrhoea, malnutrition and weight loss. AIM:To assess the efficacy and safety of pancreatin (Creon 40000 MMS) in treating PEI due to chronic pancreatitis (CP). METHODS:This was a 1-week, double-blind, randomised...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2012.05202.x

    authors： Thorat V,Reddy N,Bhatia S,Bapaye A,Rajkumar JS,Kini DD,Kalla MM,Ramesh H

    更新日期：2012-09-01 00:00:00